The microbiota and immune response during Clostridium difficile infection

Anaerobe

Volumn 41, Issue , 2016, Pages 79-84

  Buonomo, Erica L ^a   Petri, William A ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Clostridium difficile; Colitis; Fecal transplant; Immune response; Inflammation; Innate; Microbiota

Indexed keywords

FIDAXOMICIN; IMMUNOGLOBULIN A; METRONIDAZOLE; VANCOMYCIN;

ARTICLE; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE INFECTION; COLON; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; GASTROENTERITIS; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; IMMUNE RESPONSE; MICROFLORA; NONHUMAN; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RISK FACTOR; SYMPTOMATOLOGY; UNITED STATES; ADAPTIVE IMMUNITY; ANIMAL; COLITIS; DISEASE PREDISPOSITION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE FLORA; MICROBIOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; CLOSTRIDIUM DIFFICILE; COLITIS; DISEASE SUSCEPTIBILITY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNITY, INNATE;

EID: 84969919884     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2016.05.009     Document Type: Article

References (73)

1. [1] Maroo, S., Lamont, J.T., Recurrent clostridium difficile. Gastroenterology 130 (2006), 1311–1316.
2. [2] Rupnik, M., Wilcox, M.H., Gerding, D.N., Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7 (2009), 526–536.
3. [3] Miller, B.A., Chen, L.F., Sexton, D.J., Anderson, D.J., Comparison of the burdens of hospital-onset, healthcare facility–associated clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant staphylococcus aureus in community hospitals. Infect. Control Hosp. Epidemiol. 32 (2011), 387–390.
4. [4] Lessa, F.C., et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372 (2015), 825–834.
5. [5] Loo, V.G., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–Associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353 (2005), 2442–2449.
6. [6] Dubberke, E.R., Olsen, M.A., Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 55 (2012), S88–S92.
7. [7] Gerding, D.N., Muto, C.A., Owens, R.C. Jr., Treatment of Clostridium difficile infection. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 46:Suppl. 1 (2008), S32–S42.
8. [8] Aslam, S., Hamill, R.J., Musher, D.M., Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5 (2005), 549–557.
9. [9] Garey, K.W., Sethi, S., Yadav, Y., DuPont, H.L., Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J. Hosp. Infect. 70 (2008), 298–304.
10. [10] H. L. DuPont, Diagnosis and management Clostridium difficile infection. Clin. Gastroenterol. Hepatol. doi:10.1016/j.cgh.2013.03.016.
11. [11] Carroll, K.C., Bartlett, J.G., Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu. Rev. Microbiol. 65 (2011), 501–521.
12. [12] Denève, C., Janoir, C., Poilane, I., Fantinato, C., Collignon, A., New trends in Clostridium difficile virulence and pathogenesis. Int. J. Antimicrob. Agents 33:Suppl. 1 (2009), S24–S28.
13. [13] Pépin, J., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ Can. Med. Assoc. J. J. Assoc. Med. Can. 171 (2004), 466–472.
14. [14] Madan, R. Jr., Petri, W.A. Jr., Immune responses to Clostridium difficile infection. Trends Mol. Med. 18 (2012), 658–666.
15. [15] Hundsberger, T., et al. Transcription analysis of the genes tcda-e of the pathogenicity locus of Clostridium Difficile. Eur. J. Biochem. 244 (1997), 735–742.
16. [16] Shen, A., Clostridium difficile toxins: mediators of inflammation. J. Innate Immun. 4 (2012), 149–158.
17. [17] Schirmer, J., Aktories, K., Large clostridial cytotoxins: cellular biology of Rho/Ras-glucosylating toxins. Biochim. Biophys. Acta BBA - Gen. Subj. 1673 (2004), 66–74.
18. [18] Warny, M., Vaerman, J.P., Avesani, V., Delmée, M., Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 62 (1994), 384–389.
19. [19] Pothoulakis, C., Effects of Clostridium difficile toxins on epithelial cell barrier. Ann. N. Y. Acad. Sci. 915 (2000), 347–356.
20. [20] Savidge, T.C., et al. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125 (2003), 413–420.
21. [21] Loo, V.G., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353 (2005), 2442–2449.
22. [22] Chen, X., et al. A mouse model of clostridium difficile–associated disease. Gastroenterology 135 (2008), 1984–1992.
23. [23] van der Waaij, D., Vries, J.M.B., der Wees, J.E.C.L., Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J. Hyg. (Lond.) 69 (1971), 405–411.
24. [24] Full Text PDF.
25. [25] Merrigan, M.M., Sambol, S.P., Johnson, S., Gerding, D.N., Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188 (2003), 1922–1927.
26. [26] Ferreyra, J.A., et al. Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. Cell Host Microbe 16 (2014), 770–777.
27. [27] Ng, K.M., et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature, 502, 2013.
28. [28] Wilson, K.H., Sheagren, J.N., Freter, R., Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J. Infect. Dis. 151 (1985), 355–361.
29. [29] Sorg, J.A., Sonenshein, A.L., Bile salts and glycine as cogerminants for clostridium difficile spores. J. Bacteriol. 190 (2008), 2505–2512.
30. [30] Sorg, J.A., Sonenshein, A.L., Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192 (2010), 4983–4990.
31. [31] Theriot, C.M., Young, V.B., Interactions between the gastrointestinal microbiome and clostridium difficile. Annu. Rev. Microbiol. 69 (2015), 445–461.
32. [32] Buffie, C.G., et al. Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile. Nature 517 (2015), 205–208.
33. [33] Lawley, T.D., et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing clostridium difficile disease in mice. PLoS Pathog., 8, 2012, e1002995.
34. [34] Tvede, M., Rask-Madsen, J., Bacteriotherapy for chronic relapsing clostridium difficile diarrhoea in six patients. Lancet 333 (1989), 1156–1160.
35. [35] van Nood, E., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368 (2013), 407–415.
36. [36] Hasegawa, M., et al. Nucleotide-binding oligomerization domain 1 mediates recognition of Clostridium difficile and induces neutrophil recruitment and protection against the pathogen. J. Immunol. 186 (2011), 4872–4880.
37. [37] Jarchum, I., Liu, M., Shi, C., Equinda, M., Pamer, E.G., Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect. Immun. 80 (2012), 2989–2996.
38. [38] Ryan, A., et al. A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog., 7, 2011, e1002076.
39. [39] Lawley, T.D., et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect. Immun. 77 (2009), 3661–3669.
40. [40] Madan, R., et al. Role of leptin-mediated colonic inflammation in defense against C. difficile colitis. Infect. Immun., 2013, 10.1128/IAI.00972-13.
41. [41] Abt, M.C., et al. Innate immune defenses mediated by two ILC subsets are critical for protection against acute Clostridium difficile infection. Cell Host Microbe 18 (2015), 27–37.
42. [42] Geiger, T.L., et al. Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J. Exp. Med. 211 (2014), 1723–1731.
43. [43] Hasegawa, M., et al. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity 41 (2014), 620–632.
44. [44] Bulusu, M., Narayan, S., Shetler, K., Triadafilopoulos, G., Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am. J. Gastroenterol. 95 (2000), 3137–3141.
45. [45] El Feghaly, R.E., Stauber, J.L., Tarr, P.I., Haslam, D.B., Intestinal inflammatory Biomarkers and outcome in pediatric Clostridium difficile infections. J. Pediatr., 163, 2013 1697–1704.e2.
46. [46] El Feghaly, R.E., et al. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 56 (2013), 1713–1721.
47. [47] Garey, K.W., et al. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent clostridium difficile infection. Clin. Infect. Dis. 51 (2010), 1406–1410.
48. [48] Buonomo, E.L., et al. Role of IL-23 signaling in Clostridium difficile colitis. J. Infect. Dis. jit, 277, 2013, 10.1093/infdis/jit277.
49. [49] Xu, H., et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513 (2014), 237–241.
50. [50] Cowardin, C.A., et al. Inflammasome activation contributes to interleukin-23 production in response to Clostridium difficile. mBio, 6, 2015.
51. [51] Ishida, Y., et al. Essential involvement of IFN-γ in Clostridium difficile toxin a-induced enteritis. J. Immunol. 172 (2004), 3018–3025.
52. [52] Ng, J., et al. Clostridium difficile toxin–induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology, 139, 2010 542–552.e3.
53. [53] Belkaid, Y., Hand, T.W., Role of the microbiota in immunity and inflammation. Cell 157 (2014), 121–141.
54. [54] Sansonetti, P.J., Santo, J.P.D., Debugging how bacteria manipulate the immune response. Immunity 26 (2007), 149–161.
55. [55] Lathrop, S.K., et al. Peripheral education of the immune system by colonic commensal microbiota. Nature 478 (2011), 250–254.
56. [56] Arpaia, N., et al. Metabolites produced by commensal bacteria promote peripheral regulatory T cell generation. Nature, 504, 2013.
57. [57] Round, J.L., Mazmanian, S.K., The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9 (2009), 313–323.
58. [58] Pelletier, M., et al. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115 (2010), 335–343.
59. [59] Deplancke, B., Gaskins, H.R., Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am. J. Clin. Nutr. 73 (2001), 1131S–1141S.
60. [60] Shan, M., et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 342 (2013), 447–453.
61. [61] Burgess, S.L., et al. Bone marrow dendritic cells from mice with an altered microbiota provide interleukin 17A-dependent protection against entamoeba histolytica colitis. mBio, 5, 2014.
62. [62] Knoop, K.A., McDonald, K.G., Kulkarni, D.H., Newberry, R.D., Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut gutjnl, 2015, 10.1136/gutjnl-2014-309059 2014–309059.
63. [63] Amar, J., et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol. Med. 3 (2011), 559–572.
64. [64] Macpherson, A.J., McCoy, K.D., Stratification and compartmentalisation of immunoglobulin responses to commensal intestinal microbes. Semin. Immunol. 25 (2013), 358–363.
65. [65] Crabbé, P.A., Bazin, H., Eyssen, H., Heremans, J.F., The normal microbial flora as a major stimulus for proliferation of plasma cells synthesizing IgA in the gut. The germ-free intestinal tract. Int. Arch. Allergy Appl. Immunol. 34 (1968), 362–375.
66. [66] Johal, S.S., et al. Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea. J. Clin. Pathol. 57 (2004), 973–979.
67. [67] Bauer, M.P., Nibbering, P.H., Poxton, I.R., Kuijper, E.J., Dissel, J., van, T., Humoral immune response as predictor of recurrence in Clostridium difficile infection. Clin. Microbiol. Infect. 20 (2014), 1323–1328.
68. [68] Leav, B.A., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28 (2010), 965–969.
69. [69] Zaph, C., et al. Commensal-dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine. J. Exp. Med. 205 (2008), 2191–2198.
70. [70] Zhao, A., et al. Critical role of IL-25 in nematode infection-induced alterations in intestinal function. J. Immunol. Balt. Md 1950:185 (2010), 6921–6929.
71. [71] Kleinschek, M.A., et al. IL-25 regulates Th17 function in autoimmune inflammation. J. Exp. Med. 204 (2007), 161–170.
72. [72] Brandt, L.J., Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol. Hepatol. 8 (2012), 191–194.
73. [73] Kociolek, L.K., Gerding, D.N., Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 150–160.